Mimotope Peptides Induce Antibodies to Clear Alpha-Synuclein Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for synucleinopathies, such as Parkinson's disease and Multiple System Atrophy, primarily offer symptomatic relief without halting disease progression, and there is a need for a therapeutic approach that targets the underlying neuronal accumulation of alpha-synuclein protein.
Innovation Solution
Development of a peptide or polypeptide with a specific amino acid sequence that induces the formation of antibodies targeting alpha-synuclein, reducing its accumulation and oligomerization, thereby treating and preventing synucleinopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If symptomatic medications (L-dopa, anticholinergic drugs, MAO inhibitors) are used, then symptoms are alleviated, but disease progression is not halted and no long-lasting disease-modifying effect is achieved
Solution Approach 1:
The patent uses the harmful accumulated alpha-synuclein protein itself as the target for therapeutic intervention. By designing peptides that mimic alpha-synuclein epitopes, the invention converts the pathogenic protein into a therapeutic target, enabling the immune system to recognize and clear the harmful aggregates while preventing further disease progression
Solution Approach 2:
The patent introduces synthetic peptides as intermediaries that bridge the gap between the immune system and alpha-synuclein aggregates. These peptides serve as mediators by binding to antibodies and facilitating the clearance of pathological alpha-synuclein without directly interacting with the complex neurodegenerative processes
2Stability of the object's composition
If alpha-synuclein accumulates in Lewy bodies, then characteristic pathologic lesions form, but neuronal function deteriorates and neurodegeneration progresses
Solution Approach 1:
The patent extracts the immunogenic epitope information from the alpha-synuclein protein sequence and uses it to design synthetic peptides. These peptides are then used to generate antibodies that specifically target and remove pathological alpha-synuclein aggregates from neurons, thereby extracting the harmful component while preserving neuronal function
Solution Approach 2:
The patent changes the physical and chemical parameters of alpha-synuclein by focusing on specific epitopic regions (amino acid sequences) that are most immunogenic and pathologically relevant. By targeting these specific parameters rather than the entire protein, the therapy achieves selective clearance of pathological forms while minimizing effects on normal protein function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed peptides and polypeptides effectively induce antibodies that bind to alpha-synuclein, reducing its levels and oligomerization, providing a potential disease-modifying treatment for synucleinopathies by promoting the degradation of alpha-synuclein aggregates and preventing neurodegeneration.
Implementation Method 1
The proposed peptides and polypeptides effectively induce antibodies that bind to alpha-synuclein, reducing its levels and oligomerization
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to peptides or polypeptides for producing medicaments for preventing and/or treating synucleinopathies.